ASLAN004-003: A randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe atopic dermatitis.
Clinical trial for adults (age > 18) with at least a 6-month history of atopic dermatitis. In terms of severity, the trial requires a BSA involvement of >10% (and a minimum EASI score of 16). A subset of patients with prior dupixent exposure will be permitted to enter the study.
Study length: 16 weeks.